Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

Inclusion Criteria:

• Treatment-compliant patients who are participating in qualifying ongoing studies andhave completed required End-of-Treatment and/or Follow-up visits in a prior clinicalstudy with bardoxolone methyl

Exclusion Criteria:

• Participation in other investigational clinical studies involving interventionalproducts being tested or used in a way different from the approved form or when usedfor an unapproved indication;
• Patients who have an ongoing SAE from a clinical study that is assessed by theinvestigator as related to bardoxolone methyl;
• Unwilling to practice acceptable methods of birth control (both males who havepartners of childbearing potential and females of childbearing potential) while takingstudy drug;
• Women who are pregnant or breastfeeding;
• Patient is, in the opinion of the investigator, unable to comply with the requirementsof the study protocol or is unsuitable for the study for any reason;
• Known hypersensitivity to any component of the study drug